Evidence map›Paper›PMID 29746485›Full record

ArticlePloS one2018

Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.

Obiageli Offor, Netanya Utay, David Reynoso, Anoma Somasunderam, Judith Currier, Jordan Lake

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00656175 (Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00656175 phase2completednot on this map

Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation

TypeinterventionalSponsorUniversity of California, Los AngelesRan2008 to 2011Enrolled39ConditionsHIV Infections, LipodystrophyArmsraltegravir
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Obiageli OfforDepartment of Epidemiology, University of Texas Health Science Center Houston, Texas, United States of America.ORCID 0000-0002-0977-5668
Netanya UtayDepartment of Internal Medicine, University of Texas Health Science Center Houston, Texas, United States of America.
David ReynosoDepartment of Infectious Disease, University of Texas Medical Branch Galveston, Texas, United States of America.
Anoma SomasunderamDepartment of Internal Medicine, University of Texas Health Science Center Houston, Texas, United States of America.
Judith CurrierDepartment of Infectious Disease, University of California Los Angeles, California, United States of America.
Jordan LakeDepartment of Infectious Disease, University of Texas Health Science Center Houston, Texas, United States of America.
The University of Texas Health Science Center at Houston · USThe University of Texas Medical Branch at Galveston · USUniversity of California, Los Angeles · US

Funding

ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
UCLA OLDER AMERICANS INDEPENDENCE CENTERP30AG028748 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MOORE, ALISON AHERN · 2006 to 2017
$9.8M
Postdoctoral Training in Global AIDS Prevention ResearchT32MH080634 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESSE LAWTON CLARK, Pamina Mae Gorbach · 2007 to 2026
$6.4M
Optimizing Antiretroviral Therapy in HIV K24AI056933 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 2003 to 2013
$1.4M
Inflammation, Fibrosis and End-Organ Disease in HIV-Infected AdultsK23AI110532 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LAKE, JORDAN E · 2014 to 2018
$937k
NCRR NIH HHS M01 RR000865NIAID NIH HHS K23 AI110532NIAID NIH HHS K24 AI056933NIAID NIH HHS P30 AI028697NIA NIH HHS P30 AG028748NIH HHS K24 AI56933NIH HHS M01-RR000865NIH HHS P30-AG028748NIH HHS T32 MH080634NIMH NIH HHS T32 MH080634
6 · The paper itself

Abstract

backgroundPeople with HIV are at for metabolic syndrome (MetS) and fatty liver disease, but the role of Antiretroviral therapy (ART) is poorly understood. MetS and fatty liver disease been associated with changes in adiponectin, soluble ST2 (sST2), chitinase 3-like 1 (Chi3L1), hyaluronic acid (HA), tissue inhibitor of metalloproteinase-1 (TIMP-1), lysyl oxidase-like-2 (LOXL2) and transforming growth factor β (TGF-β) concentrations in HIV-uninfected populations. Protease (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) may contribute to these comorbidities, but the effects of switching from PI- or NNRTI to raltegravir (RAL) on these biomarkers is unknown.

methodsCryopreserved plasma was obtained from a completed, prospective trial of HIV-infected women with central adiposity on NNRTI- or PI-based ART during which they were randomized to remain on their current ART or switch to a RAL based regimen. Biomarker concentrations were quantified using ELISA and Multiplex assays at baseline and 24 weeks after randomization. Wilcoxon-signed rank test evaluated within-group changes, Spearman and linear regression models evaluated correlations between biomarkers and clinical covariates.

resultsParticipants had a median age of 43 years, CD4+ T lymphocyte count 558 cells/mm3 and BMI 32 kg/m2; 35% met criteria for MetS. At baseline, higher adiponectin levels correlated with higher Chi3L1 levels (r = 0.42, p = 0.02), as did declines after 24 weeks (r = 0.40, p = 0.03). Changes in sST2 correlated with changes in Chi3L1 (r = 0.43, p = 0.02) and adiponectin (r = 0.40, p = 0.03). Adiponectin and Chi3L1 levels decreased significantly in women switched to RAL vs continue PI/NNRTI.

conclusionIn women with HIV and central obesity, the hepatic steatosis/fibrosis marker Chi3L1 and adiponectin decrease in conjunction with sST2 decreases following switch to RAL. Whether switching from NNRTI/PI-based regimens to RAL can improve hepatic steatosis and dysmetabolism requires further study.

trial registrationClinicaltrials.gov NCT00656175.

Indexed as

AdiponectinAdultAmino Acid OxidoreductasesAnti-HIV AgentsBiomarkersCD4 Lymphocyte CountChitinase-3-Like Protein 1Fatty LiverFemaleHIV InfectionsHIV Protease InhibitorsHumansMetabolic SyndromeMiddle AgedObesityProspective StudiesAdiponectinAmino Acid OxidoreductasesAnti-HIV AgentsBiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1HIV Protease InhibitorsLOXL2 protein, humanRaltegravir PotassiumReverse Transcriptase InhibitorsTissue Inhibitor of Metalloproteinase-1

Identifiers

PMID29746485
PMCPMC5944924
OpenAlexW2803043567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.